Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

NCT04512716 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

B-ALL
DLBCL
B ALL
Dlbcl-Ci
DLBCL Unclassifiable
DLBCL, Nos Genetic Subtypes
DLBCL Activated B-Cell Type
DLBCL Germinal Center B-Cell Type
Diffuse Large B-cell Lymphoma
HGBL
HGBL, Nos

Interventions

DRUG: 131-I Apamistamab
BIOLOGICAL: CAR T-cell

Sponsor

Memorial Sloan Kettering Cancer Center